Two upsized US IPOs priced in the early hours of October 16, 2026: City Therapeutics raised $200 million at $18 per share, and Strive priced an upsized $630 million offering of preferred stock at $90 per share. Here is what the headlines actually confirm, what remains unknown, and what a retail holder can check right now without guessing.
What happened with the City Therapeutics and Strive IPOs?
Two separate upsized US IPOs priced within hours of each other overnight into October 16, 2026, each corroborated by multiple independent newsrooms. The first is City Therapeutics, a company that raised $200 million by pricing its IPO at $18 per share. The second is Strive, which priced an upsized offering of preferred stock at $90 per share, raising roughly $630 million.
Both deals were described as upsized, meaning the companies sold more stock than originally planned. Beyond those figures, the headlines do not yet confirm the first trading day, the exchange tickers, or how the shares will behave once open. Where a detail is not in the headlines, we say so rather than invent it.
- City Therapeutics: upsized IPO, $18 per share, $200 million raised (Bloomberg, Investing, ~90-147 minutes before publication).
- Strive: upsized IPO of preferred stock, $90 per share, approximately $630 million (Seeking Alpha, Investing, ~18-147 minutes before publication).
What does an "upsized" IPO actually mean?
An upsized IPO means the issuer increased the number of shares offered, or the price, or both, before pricing, usually because demand from institutional buyers was stronger than the initial range suggested. It is a signal of order-book appetite at the time of pricing, not a guarantee of how the stock trades afterward.
Why the distinction between common and preferred stock matters
These two deals are not the same kind of security, and that difference is the single most important thing for a retail reader to understand today.
- City Therapeutics priced common stock at $18, the familiar equity that moves with company performance and sentiment.
- Strive priced preferred stock at $90. Preferred shares typically sit higher in the capital structure and often carry a fixed dividend, behaving more like an income instrument than a growth bet.
The headlines confirm Strive's security is preferred stock but do not state the dividend rate, any call terms, or the ticker. Treat those as unknown for now.
| Detail | City Therapeutics | Strive |
|---|---|---|
| Security type | Common stock | Preferred stock |
| Price | $18 / share | $90 / share |
| Amount raised | ~$200 million | ~$630 million |
| Upsized? | Yes | Yes |
Why do two upsized IPOs on the same morning matter to retail investors?
Two upsized deals pricing in the same window suggests the new-listings window was open enough overnight for issuers to push size, at least across these two names. That is a read on primary-market demand, not a forecast for your existing holdings.
For most retail investors, the practical point is simpler. A newly listed stock has no trading history, so the early sessions can be volatile, and the pricing level is a starting reference, not a floor or ceiling. If you are weighing how new listings fit alongside what you already own, our guide on tracking positions in a portfolio tracker versus a spreadsheet covers why a live view beats a static one for fast-moving names.
How can a PortfolioTrackr user check their exposure right now?
Start by checking whether you already hold either name or anything closely related, because exposure you forgot about is the most common surprise on an IPO morning. In PortfolioTrackr, your ALL PORTFOLIOS combined view shows every position across your accounts in one place, which is the fastest way to confirm.
Three checks that are not advice
Checking your own numbers is not the same as acting on them. Here is what a holder can do today without anyone telling them to trade:
- Confirm exposure: search your holdings for the names and any sector-adjacent positions you already own.
- Review allocation: look at how much of your portfolio a single new or speculative position would represent against everything else.
- Check your targets: if you do hold a related name, see where it sits against your own Target 1, Target 2, and stop-loss levels.
Every connected broker in PortfolioTrackr gets its own read-only portfolio, and that broker portfolio does not count toward your portfolio limit, so adding one does not cost you a slot. If you want to link an account to see holdings automatically, our walkthrough on connecting a brokerage account to a portfolio tracker explains the options.
How do I set a price alert on a new listing in PortfolioTrackr?
You add the ticker to your watchlist and set a price level, either above or below, and PortfolioTrackr checks it once a minute while the market is open and tells you within a minute of your level being hit. For a brand-new listing with no price history, a watchlist level is often more useful than an alert on a position you do not yet hold.
A few specifics worth knowing before the first bell:
- The watchlist holds 10 tickers on the free trial and Starter, and 50 tickers on Pro and Lifetime.
- Alerts are price levels only: a price above or below on a watchlist entry, or Target 1, Target 2 and a stop-loss on a position you hold. There are no IPO-event or news alerts.
- Email, WhatsApp, Telegram and push alerts are on every plan; SMS is Pro and Lifetime only.
Because a stock's market is closed overnight, the check pauses until the opening bell, which matters for an IPO that lists on a specific session. PortfolioTrackr reports status against your own levels, such as still below target or stop-loss level reached, and never tells you what to do next.
What about currency if either listing trades outside your home market?
If you buy a US-listed share in a non-USD account, the currency it settles in affects your real return, and this is something retail investors routinely miss. PortfolioTrackr tracks this directly: the cost of a holding is converted at the exchange rate of the day it was bought, and its value at today's rate, with the currency gain or loss shown as its own line on the summary card and the P&L chart.
That separation matters most when a position moves fast, because it tells you how much of your gain or loss came from the stock versus the currency. PortfolioTrackr covers 100 currencies for display and conversion, with 10 years of daily exchange rates behind the math.
What is still unknown, and what should you watch next?
Several details that matter for both deals are not yet confirmed by the headlines, and it is better to say so than to guess.
- The first trading day and opening price for each listing.
- The ticker symbols and the exchange each will list on.
- For Strive, the preferred stock's dividend rate, any call or conversion terms, and maturity.
- For City Therapeutics, the business detail, pipeline stage, and use of the $200 million raised.
What a holder can watch, concretely, is the first-day open versus the pricing level ($18 for City Therapeutics, $90 for Strive), the published tickers so you can add them to a watchlist, and any official filing that confirms the terms. For a new biotech name specifically, early volatility around the first few sessions is normal, and a watchlist level lets the app flag movement within a minute rather than you refreshing a quote page.
If you track both stocks and crypto in one place, the same exposure-and-alert routine applies across asset classes, as we cover in our guide to tracking stocks and crypto together in one app.
The bottom line
As of October 16, 2026, two upsized US IPOs have priced overnight: City Therapeutics at $18 per share for $200 million, and Strive at $90 per share in preferred stock for roughly $630 million. The strong demand implied by both upsizings is a fact about the pricing moment, not a prediction about how either trades.
The useful moves for a retail investor are the unglamorous ones: confirm whether you have exposure, review how any new position would sit against your existing allocation, and set a watchlist price alert if you want to be told when a level is hit. PortfolioTrackr handles all three without ever deciding for you.
Track your portfolio in real time: free for 3 days
Live P&L across stocks, crypto, and global markets. WhatsApp and Telegram price alerts. AI trade import. Unified dividend tracking. No brokerage connection required.
Start Free Trial
Frequently asked questions
What price did City Therapeutics IPO price at?
City Therapeutics priced its upsized IPO at $18 per share, raising $200 million, as confirmed by Bloomberg and Investing on October 16, 2026. The headlines do not yet state the ticker symbol, exchange, or first trading day, so treat those details as not yet confirmed.
How much did Strive raise in its preferred stock IPO?
Strive priced an upsized IPO of preferred stock at $90 per share, raising roughly $630 million, according to Seeking Alpha and Investing on October 16, 2026. The dividend rate, call terms, maturity and ticker were not confirmed in the headlines.
What does an upsized IPO mean for investors?
An upsized IPO means the company sold more shares, or priced higher, than originally planned, usually because demand was stronger than the initial range. It signals order-book appetite at pricing time but does not guarantee how the stock trades once listed.
Can I set a price alert on a brand new IPO in PortfolioTrackr?
Yes. Add the ticker to your watchlist and set a price level above or below. PortfolioTrackr checks it once a minute while the market is open and alerts you within a minute of your level being hit. Watchlists hold 10 tickers on free and Starter plans, 50 on Pro and Lifetime.
What is the difference between common and preferred stock in these IPOs?
City Therapeutics priced common stock at $18, which moves with company performance. Strive priced preferred stock at $90, which typically sits higher in the capital structure and often pays a fixed dividend, behaving more like an income instrument than a growth position.